• UCLA Health
  • myUCLAhealth
  • School of Medicine
UCLA Urology

UCLA Urology

UCLA Urology
  • About Us
    • Chair's Welcome
    • Awards and Recognition
    • Innovations and Technology
    • UCLA Institute of Urologic Oncology
    • Webinars
    • Contact Us
    • News and Events
    • Newsletters
    • Our History
    • Our Milestones
    • The Men's Clinic at UCLA
    • Jobs
    • Giving
  • Clinical Programs
    • Bladder Cancer
    • General Adult Urology
    • Kidney Cancer
    • Kidney Stone Center
    • Kidney Transplant Program
    • Male Urology
    • Minimally Invasive/Robotics Surgery
    • Pediatric Urology Program
    • Pelvic Medicine and Reconstruction
    • Prostate Cancer Program
    • Testicular Cancer
    • Urologic Oncology
    • Conditions Treated
  • Clinical Trials
    • Find a Doctor
    • Frequently Asked Questions (FAQ)
    • Learn More About Clinical Trials
  • For Patients
    • COVID-19 Message to Our Patients
    • Get an Expert Second Opinion
    • Telemedicine Visits Available
    • Appointment Request
    • myUCLAhealth
    • Contact Us
    • Maps and Directions
    • Clinical Updates
    • Preparing for Surgery
    • Interactive Procedure Videos
    • Patient Education
    • Patient Stories
    • Video Gallery
    • Webinars
    • Vital Signs Publications
    • UCLA Blood Donation
    • UCLA Overnight Accommodations
    • Urology Portal
  • Research
    • Bladder Cancer Research
    • Kidney Cancer Research
    • Male Urology Research
    • Pediatric Urology Research
    • Prostate Cancer Research
    • SPORE In Prostate Cancer
    • Health Services Research
    • Faculty Publications
  • Education
    • Housestaff Roster 2020-21
    • Residency
    • Fellowships
    • Medical Student Program
    • Aerial Tour: Why Choose UCLA?
  • For Healthcare Professionals
    • How to Refer a Patient
    • Physicians Updates & Clinical Updates
    • Events and CME Courses
    • eReferrals
  • Physician Directory
    • UCLA Faculty and Providers
    • Joint Appointments/Research Faculty
  • UCLA Health
  • myUCLAhealth
  • School of Medicine

UCLA Urology

Clinical Trials

  1. Home
  2. Clinical Programs
  3. Kidney Cancer
  4. Clinical Trials

Clinical Trials

Share this
IUO
Request An Appointment

Phone: (310) 794-7700

UCLA Urology Clinical Trials for Kidney Cancer

A clinical trial is a study conducted with actual patients, usually to evaluate a new treatment. Each study is designed to answer scientific questions and to find new and better ways to help patients.

Ongoing Clinical Trials for Kidney Cancer:

HLRCC Repository

Technical Title: Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC): Data and Biospecimen Repository 
Disease Type: Patients with a diagnosis of HLRCC as a result of 1) a genetic alteration in the fumarate hydratase (FH) gene or 2) have clinical features and a family history of an alteration in the FH gene.
Basic information: Hereditary leiomyomatosis and renal cell cancer (HLRCC) is a disorder in which affected individuals tend to develop benign tumors containing smooth muscle tissue (leiomyomas) in the skin and, in females, the uterus. This condition also increases the risk of kidney cancer. The purpose of this study is to construct a biologic specimen bank for research purposes. Determining which additional factors contribute to the development of HLRCC manifestations, detecting biomarkers that may lead to earlier diagnosis, and learning more about the clinical outcomes with treatment strategies is the ultimate goal of the research. This biologic specimen bank will study the genetic and biological factors contributing to the development of Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC).

For More Detailed Information, Contact:

  • Brian Shuch, MD, Principal Investigator
  • Shirin Zavoshi, MD, (310) 794-9493
  • Brian Shuch, MD, Principal Investigator
  • Shirin Zavoshi, MD, (310) 794-9493

Stool Microbiome and Immunotherapy Study

Technical Title: Stool Microbiome and Immunotherapy Response and Toxicity
Disease Type: Patients with recently diagnosed metastatic kidney cancer (mRCC) or metastatic urothelial carcinoma (mUC) and new prescription for immunotherapy.
Basic information: Cancer immunotherapy is now used in many cancers including drugs which block a specific pathway (PD-1). Exciting data has linked the response to immune therapy with the type of stool bacteria that live in the gut. We now have the potential to study the bacteria which live in one’s gut by testing the stool. We still do not know which stool bacteria are associated with better response, but if this is discovered in the future, there is the potential to alter the bacteria in order to improve outcome with these cancer therapies. We are performing this study in order to better understand which bacteria are present in our patients and if it changes with therapy. We hope to obtain more information on which bacteria (if any) are associated with an improved outcome and less toxicity to inform future work in this area.

For More Detailed Information, Contact:

  • Brian Shuch, MD, Principal Investigator
  • Shirin Zavoshi, MD, (310) 794-9493

The Enhanced Renal Mass Biopsy  

Technical Title: The Enhanced Renal Mass Biopsy: Impact on Clinical Decision-Making for the Localized Renal Mass
Disease Type: Individuals who have a renal mass and a prior renal biopsy but have not yet decided on management.
Basic information: Renal masses may be cancer or benign tumors. Renal biopsies can sample the tissue prior to treatment. There are limitations of what a biopsy can provide and often patients proceed with surgery due to uncertainty about the aggressiveness of the tumor. Genetic analyses are possible on the tissue removed from a biopsy and can provide further information on a tumor’s future behavior. We are interested in understanding how this genetic information can help a patient decide on which treatment may be best for them.       

For More Detailed Information, Contact:

  • Brian Shuch, MD, Principal Investigator
  • Shirin Zavoshi, MD, (310) 794-9493

BMS Checkmate: A Study for Kidney Cancer Patients After Nephrectomy 

Technical Title: A Phase 3 Randomized, Double-Blind Study of Nivolumab Monotherapy or Nivolumab Combined with Ipilimumab Combination vs Placebo in Participants with Localized Renal Cell Carcinoma Who Underwent Radical or Partial Nephrectomy and Who Are at High Risk of Relapse
Disease Type: Patients with renal cell carcinoma (a type of kidney cancer) who are planned to have a nephrectomy (surgical removal of the kidney)
Basic information: The purpose of this study is to compare the effectiveness, safety, and tolerability of an investigational drug combination in patients with localized kidney cancer that have had their tumors completely removed, but are at risk of having their cancer return. The drug combination includes two drugs: nivolumab (also known as OPDIVO) and ipilimumab (also known as Yervoy).
For More Detailed Information, Contact:

• Brian Shuch, MD, Principal Investigator 
• Sara Rodriguez, Study Coordinator, (310) 794-2877

Read more about this study (NCT03138512) on ClinicalTrials.gov.


Sestamibi Imaging for the Characterization of Renal Masses 

Technical Title: 99mTc-sestamibi Imaging for the Characterization of Renal Masses:
Impact on Clinical Decision Making
Disease Type: Patients with recently diagnosed renal masses
Basic information: The purpose of this study is to examine how doctors and patients use information from 99mTc-sestamibi SPECT/CT, a type of nuclear medicine scan, to decide how to manage newly diagnosed renal masses (kidney tumors). Patients on this study will undergo 99mTc-sestamibi SPECT/CT scans as part of their routine care.
For More Detailed Information, Contact:

• Brian Shuch, MD, Principal Investigator 
• Sara Rodriguez, Study Coordinator, (310) 794-2877


Testing the Addition of the Drug Nivolumab Before and After Surgery for Renal Cell Carcinoma 

Technical Title: PROSPER RCC:  EA8143: A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients with Localized Renal Cell Carcinoma Undergoing Nephrectomy
Disease Type: Patients with renal cell carcinoma (a type of kidney cancer) who are planned to have a nephrectomy (surgical removal of the kidney)
Basic information: The purpose of this study is to compare the effects of a drug called nivolumab (also known as OPDIVO®), before and after the kidney cancer surgery to using the usual approach of surgically removing the kidney cancer followed by standard post-operative follow-up and monitoring. Nivolumab is a drug that may help stimulate your immune system to attack any cancer cells that may remain after surgery. The addition of nivolumab to the usual surgery could prevent your cancer from returning but it could also cause side effects.
For More Detailed Information, Contact:

• Brian Shuch, MD, Principal Investigator 
• Rosleen Mala, Study Coordinator, (310) 794-3879


For more information

For information on inclusion and exclusion criteria please call our Clinical Trials Office - 310-206-5930

  • Frequently Asked Questions
  • UCLA Office of Clinical Trials
  • UCLA Jonsson Comprehensive Cancer Center
  • Apply for any of the UCLA Urology clinical trials

 

Like Us on Facebook Follow Us on Twitter Subscribe to Our Videos on YouTube Follow us on Instagram Connect with Us on LinkedIn Follow us on Pinterest
UCLA Health hospitals ranked best hospitals by U.S. News & World Report
  • UCLA Health
  • Find a Doctor
  • School of Medicine
  • School of Nursing
  • UCLA Campus
  • Directory
  • Newsroom
  • Subscribe
  • Patient Stories
  • Giving
  • Careers
  • Volunteer
  • International Services
  • Privacy Practices
  • Nondiscrimination
  • Billing
  • Health Plans
  • Emergency
  • Report Broken Links
  • Terms of Use
  • 1-310-825-2631
  • Maps & Directions
  • Contact Us
  • Your Feedback
  • Report Misconduct
  • Get Social
  • Sitemap
Like Us on Facebook Follow Us on Twitter Subscribe to Our Videos on YouTube Follow us on Instagram Connect with Us on LinkedIn Follow us on Pinterest